Clinical implications of elevated serum interleukin-6 in IgG4-related disease

Introduction Some patients with IgG4-related disease (IgG4-RD) exhibit elevated serum interleukin (IL)-6 with excessive inflammatory reactions or with repeating relapse. To date few reports pertaining to clinical implications of elevated serum IL-6 in IgG4-RD patients have been published. The aims of the current retrospective study were to investigate the clinical implications of elevated serum IL-6 in IgG4-RD patients, and to examine whether IL-6 can predict the activity and/or relapse of the disease. Materials and methods We examined the clinical picture at the onset of 43 patients who were diagnosed with IgG4-RD in our hospital and were able to measure serum IL-6 before steroid treatment. Results The median level of serum IL-6 was 2.2 pg/mL. There was a significant correlation between IL-6 and C-reactive protein (CRP) level (r = 0.397, p = 0.008), hemoglobin level (r = -0.390, p = 0.010) and albumin level (r = -0.556, p < 0.001). When 43 patients were divided into two groups by using a cut-off IL-6 of 4 pg/mL, the high IL-6 group showed higher age, lower albumin, higher CRP and higher aspartate aminotransferase (AST) (age p = 0.014, albumin p = 0.006, CRP p <0.001, AST p = 0.009). Hepatic swelling and splenomegaly were significantly more prevalent in the high IL-6 group than it was in the low IL-6 group (liver p < 0.001, spleen p = 0.020). Biliary tract involvement tended to admit more in the high IL-6 group (p = 0.060). Conclusion Serum IL-6 level at the onset of IgG4-RD may be significantly correlated with clinical inflammatory parameters and it may also be associated with involvement of the bile duct, liver, and spleen.

[1]  M. Kawakami,et al.  Consideration concerning similarities and differences between ANCA-associated vasculitis and IgG-4-related diseases: case series and review of literature , 2019, Immunologic Research.

[2]  A. Kawashima,et al.  Inflammatory features, including symptoms, increased serum interleukin-6, and C-reactive protein, in IgG4-related vascular diseases , 2018, Heart and Vessels.

[3]  T. Takeuchi,et al.  Distinct features distinguishing IgG4-related disease from multicentric Castleman’s disease , 2017, RMD Open.

[4]  Y. Kawabata,et al.  Comparison of clinical and pathological features of lung lesions of systemic IgG4‐related disease and idiopathic multicentric Castleman's disease , 2017, Histopathology.

[5]  K. Uchida,et al.  IgG4-related Disease Involving Multiple Organs with Elevated Serum Interleukin-6 Levels. , 2016, Internal medicine.

[6]  S. Oda,et al.  Interleukin-6 Levels Act as a Diagnostic Marker for Infection and a Prognostic Marker in Patients with Organ Dysfunction in Intensive Care Units , 2016, Shock.

[7]  H. Sugimoto,et al.  Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis , 2016, Gut.

[8]  J. Stone,et al.  Predictors of disease relapse in IgG4-related disease following rituximab. , 2016, Rheumatology.

[9]  Dermot Kelleher,et al.  Idiopathic multicentric Castleman's disease: a systematic literature review. , 2016, The Lancet. Haematology.

[10]  K. Harada,et al.  Multicentric Castleman Disease With Tubulointerstitial Nephritis Mimicking IgG4-related Disease: Two Case Reports , 2016, The American journal of surgical pathology.

[11]  P. Gual,et al.  Immunoglobulin G4-associated autoimmune hepatitis may be found in Western countries. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[12]  Y. Zen,et al.  Idiopathic multicentric Castleman's disease: a clinicopathologic study in comparison with IgG4-related disease , 2015, Oncotarget.

[13]  A. Komatsuda,et al.  Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease , 2014, Modern rheumatology.

[14]  T. Takenouchi,et al.  Purinergic signaling via P2Y receptors up-mediates IL-6 production by liver macrophages/Kupffer cells. , 2014, The Journal of toxicological sciences.

[15]  H. Ono,et al.  Reduction of splenic volume by steroid therapy in cases with autoimmune pancreatitis , 2013, Journal of Gastroenterology.

[16]  K. Uchida,et al.  Current concept and diagnosis of IgG4-related disease in the hepato-bilio-pancreatic system , 2013, Journal of Gastroenterology.

[17]  Wei-Chih Liao,et al.  Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis , 2012, Gut.

[18]  J. Chan,et al.  Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity. , 2012, Seminars in diagnostic pathology.

[19]  T. Hibi,et al.  Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011 , 2012, Modern rheumatology.

[20]  K. Uchida,et al.  Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis , 2011, Journal of Gastroenterology.

[21]  Y. Nakanuma,et al.  Clinical significance of immunoglobulin G4-associated autoimmune hepatitis , 2011, Journal of Gastroenterology.

[22]  Kohjiro Ueki,et al.  Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus , 2010, Journal of diabetes investigation.

[23]  S. Lonial,et al.  Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. , 2010, Journal of Clinical Oncology.

[24]  B. Petersen,et al.  Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. , 2010, Gastroenterology.

[25]  M. Falconi,et al.  Autoimmune Pancreatitis: Differences Between the Focal and Diffuse Forms in 87 Patients , 2009, The American Journal of Gastroenterology.

[26]  Hiroyuki Yamamoto,et al.  The analysis of interleukin-6 in patients with systemic IgG4-related plasmacytic syndrome--expansion of SIPS to the territory of Castleman's disease. , 2009, Rheumatology.

[27]  E. Godfrey,et al.  Splenomegaly: investigation, diagnosis and management. , 2009, Blood reviews.

[28]  H. Asaoku,et al.  Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease , 2009, Modern Pathology.

[29]  D. S̆timac,et al.  Prognostic Values of IL-6, IL-8, and IL-10 in Acute Pancreatitis , 2006, Journal of clinical gastroenterology.

[30]  O. Ueda,et al.  Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. , 2002, Cytokine.

[31]  H. Tilg,et al.  Serum levels of cytokines in chronic liver diseases. , 1992, Gastroenterology.

[32]  J. Miyazaki,et al.  IgG1 plasmacytosis in interleukin 6 transgenic mice. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Kurose Nozomu Clinicopathological Analysis between IgG4-related and Non-IgG4-related Diseases Occurring in Various Organs and Tissues: Re-evaluation of Comprehensive Diagnostic Criteria and Usefulness of Interleukin-6 Immunostaining , 2016 .

[34]  K. Okazaki,et al.  Comprehensive Diagnostic Criteria for IgG4-Related Disease , 2014 .

[35]  K. Uchida,et al.  Effective steroid pulse therapy for the biliary stenosis caused by autoimmune pancreatitis. , 2007, The American journal of gastroenterology.

[36]  Y. Shima,et al.  Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. , 2000, Blood.

[37]  K. Batts,et al.  The nature and prognostic implications of autoimmune hepatitis with an acute presentation. , 1994, Journal of hepatology.